Clinical Trials Logo

Hyperlipidemias clinical trials

View clinical trials related to Hyperlipidemias.

Filter by:

NCT ID: NCT00885872 Recruiting - Atherosclerosis Clinical Trials

Rosuvastatin Evaluation of Atherosclerotic Chinese Patients (REACH)

REACH
Start date: March 2009
Phase: Phase 4
Study type: Interventional

This study is to evaluate the effect of rosuvastatin 10-20 mg on carotid atherosclerosis progression in Chinese patients by evaluating the change in the percentage of volume of lipid rich necrotic core (LRNC) using high-resolution magnetic resonance imaging (MRI) after 24-months treatment.

NCT ID: NCT00843661 Recruiting - HIV Infections Clinical Trials

Coadministration of Ezetimibe With Fenofibrate Versus Pravastatin Monotherapy for the Treatment of Hyperlipidaemia in HIV-infected Patients

Start date: March 2009
Phase: Phase 4
Study type: Interventional

- The aim of the study is to compare the effects of coadministration of ezetimibe 10 mg/die + fenofibrate 200 mg/die versus pravastatin 40 mg/die monotherapy in HIV-infected patients treated with protease inhibitors. - Single-centre, open, randomized, controlled, prospective pilot study. - 60 patients will be enrolled in order to reach the target of 50 patients evaluable at the end of the study. The patients will be randomly assigned to a 6-month treatment with ezetimibe+fenofibrate or with pravastatin.The visit will be every month.

NCT ID: NCT00820378 Recruiting - Hypertension Clinical Trials

The Epidemiology of Aortic Diameter in China

Start date: January 2009
Phase: N/A
Study type: Observational

Aortic aneurysms are the major disease processes affecting the aorta and becoming a relatively common cause of death because of rupture or dissection. The most common location for aneurysms is the infrarenal abdominal aorta, followed by the ascending thoracic aorta. Unlike coronary heart disease, the incidence of abdominal aortic aneurysm (AAA) in the United States and Europe has been increasing, and this increase may not be due to higher levels of screening for this condition alone. Aortic diameter is central to the diagnosis of aortic aneurysm. Furthermore, it was demonstrated that non-AAA patients with an enlarged diameter of the infrarenal aortic diameter are also at high risk for all-cause mortality. And aortic root dimension was associated with several coronary artery disease (CHD) risk factors and measures of subclinical disease and was predictive of incident congestive heart failure (CHF), stroke, cardiovascular disease (CVD) mortality, and all-cause mortality, but not of incident MI. Up to now, there are limited studies on the epidemiology of aortic diameter, especially in Chinese population.

NCT ID: NCT00724217 Recruiting - Hyperlipidemia Clinical Trials

Standard Process 21 Day Purification Program Project

SPPP
Start date: July 2008
Phase: Phase 1/Phase 2
Study type: Interventional

To determine the effects of a commercially available dietary modification plus nutritional supplement regimen, the Standard Process 21 day Purification Program (SPPP), on serum lipids, C-reactive protein (CRP), homocysteine, body mass index (BMI), body weight, blood pressure, and heart rate variability (HRV) in normal weight (BMI < 26) and overweight (BMI 26 or above) participants who have total cholesterol levels over 180.

NCT ID: NCT00626041 Recruiting - Hypertension Clinical Trials

U-CHAMP: Urban Cardiovascular Health Assessment and Management Program

U-CHAMP
Start date: February 2008
Phase: N/A
Study type: Interventional

High blood pressure, elevated blood glucose and high cholesterol are related to the increased risk of stroke and heart disease. Many studies have shown that this risk can be significantly reduced by lowering blood pressure, blood glucose and cholesterol levels. Through a collaborative effort between Calgary Safeway pharmacists and Calgary Health Region family physician PCN's, U-CHAMP will deliver a program to assist in the identification and management of people with elevated blood pressure, blood glucose and cholesterol and through this effort, reduce the risk of heart disease and stroke in the urban Calgary population aged 18-85 years.

NCT ID: NCT00408824 Recruiting - Healthy Clinical Trials

Investigation of Genetic Risk of Metabolic Syndrome in Company Employee (NGK Study)

Start date: September 2006
Phase: N/A
Study type: Observational

The metabolic syndrome is a highly prevalent disorder, which causes atherosclerotic cardiovascular disease and is closely associated with insulin resistance. The alteration of the secretion of adipocytokines from accumulated visceral adipose tissue in the obese induces insulin resistance. The purpose of this study is to identify gene polymorphisms that confer susceptibility to the metabolic syndrome and to make up a new health guidance program based on genetic risk assessment. About 25% of male employees over 45 years old in a certain company are diagnosed with the metabolic syndrome in medical examination. We, the researchers at Nagoya University, will analyze gene polymorphism and various biomarkers of over 3500 company employees.

NCT ID: NCT00316641 Recruiting - Hyperlipidemia Clinical Trials

The Clinical Evaluation of Efficacy of Lipid-Lowing Tea on Hyperlipidemia Patients’ Lipid Profiles

Start date: n/a
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine whether the Lipid-lowing Tea is effective and safe in the treatment of Hyperlipidemia Patients

NCT ID: NCT00291824 Recruiting - Hypertension Clinical Trials

Cardiovascular Lifestyle Study: Effects and Expense of a Cardiovascular Risk Reduction Clinic in Primary Care

Start date: August 2004
Phase: Phase 1
Study type: Interventional

The purpose of this trial is to study the effects on risk reduction and expense of 3 approaches to the care of people with cardiovascular risk factors in a naturalistic primary care environment.

NCT ID: NCT00225849 Recruiting - Hypertension Clinical Trials

Japanese Primary Prevention Project With Aspirin

Start date: March 2005
Phase: Phase 4
Study type: Interventional

The purpose of this study is to investigate the balance between the risks and benefits of primary prevention by Aspirin in elderly Japanese patients with one or more cerebro/cardiovascular risk factors